Novartis ADR


Want a discount? Become a member by purchasing Annual Subscription!
SKU: NVS Category:


Novartis AG delivered a mixed set of results in the quarter, with revenues falling short of Wall Street expectations but above-par earnings. The last quarter for Novartis AG was marked by significant achievements, including strong sales growth and margin expansion, leading to a guidance raise for the third time in the year. Sales increased by 12%, and core operating income grew by 21% this quarter. The quarter’s success was attributed to its focus on key growth drivers and a simplified organization. Notable highlights included the remarkable growth of Entresto, reaching $1.5 billion, and the return to growth for Cosentyx. Kesimpta also showed impressive results and other products like Pluvicto and Lutathera demonstrated their potential in earlier disease settings. The pipeline for Novartis is promising, with upcoming submissions and readouts that can further contribute to the company’s growth in the coming years.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!